Description (short summary):
A number of recent highly publicised drug safety issues have shown that adverse drug reactions (ADRs) may be detected too late - when millions of patients have already been exposed. As a result, the EU-ADR funded project is working on the basis of the assumption that earlier detection is needed. Before launching a new drug onto the market, appropriate tests are conducted.
However, adverse reactions may only be detected once the drug is more heavily used. EU-ADR proposes an alternative approach towards the detection of ADR signals with the objective of overcoming the limitations of spontaneous reporting databases and providing a solid basis for large-scale monitoring of drug safety.
Number of pages: 2
Related ePractice Case: EU-ADR - Exploring and Understanding Adverse Drug Reactions